Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10399949 | 0.81 | GAA (0.42) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL11435819 | 0.81 | TERT (0.37) | HTR1AMAOASLC6A2SLC6A4ADRA1A | |
| SCHEMBL11523737 | 0.78 | ALDH1A1 (0.38) | RAPGEF4PKMKDM4EALDH1A1HPGD | |
| SCHEMBL10391373 | 0.77 | SMN1; SMN2 (0.35) | HTR1AMAOASLC6A2SLC6A4ADRA1A | |
| SCHEMBL9493873 | 0.76 | PKM (0.32) | HTR1AMAOASLC6A2SLC6A4ADRA1A | |
| SCHEMBL9622483 | 0.72 | PTGS1 (0.45) | RAPGEF4PKMALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL423607 | 0.70 | ACHE (0.34) | — | |
| SCHEMBL8643442 | 0.70 | PSMD14 (0.36) | HTR1AMAOASLC6A2SLC6A4ADRA1A | |
| SCHEMBL9623038 | 0.67 | GAA (0.38) | RAPGEF4PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL9362893 | 0.67 | ALDH1A1 (0.41) | SLC6A4PKMKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123931-B1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030055065-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2003-03-20 | — | — | US | disclosed |
| US-6492381-B1 | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP. | 2002-12-10 | — | — | US | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-0723538-B1 | TRICYCLIC CARBAMATE COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0723540-B1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6300338-B1 | AS ANTITUMOR AGENT | SCHERING CORPORATION | 2001-10-09 | — | — | US | disclosed |
| EP-1123931-A1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-5089496-A | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| WO-1992000293-A1 | BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0411048-A1 | NOVEL BENZOPYRIDO PIPERIDINE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1991-02-06 | — | — | EP | disclosed |
| WO-1990013548-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| EP-0396083-A1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORPORATION (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0341860-A1 | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use | SCHERING CORPORATION (US) | 1989-11-15 | — | — | EP | disclosed |
| WO-1989010369-A1 | NOVEL BENZOPYRIDO PIPERIDINE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-11-02 | — | — | WO | disclosed |
| EP-0330673-A1 | BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0270818-A1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988003138-A1 | BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055065-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | HTR1A 2274/4885MAOA 2698/4885SLC6A2 3242/4885 |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | HTR1A 2274/4885MAOA 2698/4885SLC6A2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.